Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: A patient-level analysis of 12 studies

Diabetes, Obesity and Metabolism

Volumn 15, Issue 9, 2013, Pages 819-825

  Riddle, M C ^a   Vlajnic, A ^b   Zhou, R ^c   Rosenstock, J ^d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b SANOFI   (France)

^c Medpace Reference Laboratories   (United States)

^d DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

Author keywords

Glycaemic control; Insulin analogues; Type 2 diabetes

Indexed keywords

CARBOHYDRATE; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADD ON THERAPY; ARTICLE; CLINICAL TRIAL; DIET RESTRICTION; DRUG DOSE TITRATION; HUMAN; HYPOGLYCEMIA; INCIDENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE;

GLYCAEMIC CONTROL; INSULIN ANALOGUES; TYPE 2 DIABETES;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84880779174     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12096     Document Type: Article

References (30)

1. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
2. Rodbard HW, Jellinger PS, Bloomgarden ZT et al. AACE/ACE glycemic control algorithm consensus panel. Endocr Pract 2009; 15: 541-559.
3. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
4. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274.
5. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: 408-416.
6. Holman RR, Farmer AJ, Davies MJ et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361: 1736-1747.
7. Gerstein HC, Yale J-F, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006; 23: 736-742.
8. Standl E, Maxeiner S, Raptis S. Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility. Horm Metab Res 2006; 38: 172-177.
9. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254-259.
10. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371: 1073-1084.
11. Yki-Järvinen H, Juurinen L, Alvarsson M et al. Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007; 30: 1364-1369.
12. Blickle J-F, Hancu N, Piletic M et al. Early initiation of insulin glargine versus lifestyle management in people with type 2 diabetes and A1c of 7-8%. Diabetes 2008; 57(Suppl. 1): A139.
13. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49: 442-451.
14. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006; 29: 554-559.
15. Meneghini LF, Taylor L, Schwartz S. Improved glycemic control with insulin glargine vs pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes. Endocr Pract 2010; 16: 588-599.
16. Determine whether glycemic control is different between Lantus & a 3rd oral agent when failure with other treatment. Available from URL: http://clinicaltrials.gov/show/NCT00046462. Accessed 26 October 2011.
17. Lantus versus Humalog Mix as add-on therapy in type diabetes patients failing sulfonylurea and metformin combination treatment. Available from URL: http://clinicaltrials.gov/ct2/show/NCT01336751. Accessed 26 October 2011.
18. Akaike H. A new look at the statistical model identification. IEEE Trans Automatic Control 1974; AC-19: 716-723.
19. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
20. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
21. Garber A, Marre M, Blonde L et al. Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single-tablet metformin-glibenclamide therapy (Glucovance) in type 2 diabetes. Diabetes Obes Metab 2003; 5: 171-179.
22. Retnakaran R, Hochman J, DeVries JH et al. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care 2004; 27: 2590-2596.
23. Chase HP, Arslanian S, White NH, Tamborlane WV. Insulin glargine versus intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes mellitus. J Pediatr 2008; 153: 547-553.
24. McEwen LN, Bilik D, Johnson SL et al. Predictors and impact of intensification of antihyperglycemic therapy in type 2 diabetes: translating research into action for diabetes (TRIAD). Diabetes Care 2009; 32: 971-976.
25. DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med 2010; 27: 309-317.
26. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 2006; 29: 2137-2139.
27. Del Prato S. Role of glucotoxicity and lipotoxicity in the pathophysiology of type 2 diabetes mellitus and emerging treatment strategies. Diabet Med 2009; 26: 1185-1192.
28. Fisman EZ, Motro M, Tenenbaum A et al. Is hypoglycaemia a marker for increased long-term mortality risk in patients with coronary artery disease? An 8-year follow-up. Eur J Cardiovasc Prev Rehabil 2004; 11: 135-143.
29. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009; 301: 1565-1572.
30. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010; 33: 1389-1394.